ERQ-03
Parkinson's Disease, ALS, Diabetes
Pre-clinicalActive
Key Facts
About ERresQ
ERresQ is developing a first-in-class platform of small molecules that regulate ER stress by modulating all three branches of the Unfolded Protein Response (UPR), a mechanism inspired by endogenous neurotrophic factors MANF and CDNF. The pipeline includes both repurposed drugs and a new chemical entity, with initial applications in neurodegenerative diseases and diabetes. The company's strategy leverages the favorable pharmacokinetics of repurposed assets to potentially accelerate clinical development and market entry following proof-of-efficacy.
View full company profile